Formylated N-heterocyclic derivatives as FGFR4 inhibitors
US10786492B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 5, 2018 |
| Grant date | Sep 29, 2020 |
| Priority date | — |
| Expiry date | Dec 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.